Edgewise Therapeutics (EWTX) Current Assets (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Current Assets of $509.8 million for Q1 2026, down 6.18% sequentially from $543.4 million in Q4 2025, and up 15.03% YoY from $443.2 million in Q1 2025.
Edgewise Therapeutics (EWTX) Current Assets (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Current Assets for 7 years, with the latest figure at $509.8 million in Q1 2026.
- Quarterly Current Assets rose 15.03% year-over-year to $509.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $509.8 million (up 15.03% YoY) and the FY2025 annual result came in at $543.4 million, up 14.28% from the prior year.
- Current Assets retreated to $509.8 million in Q1 2026 per EWTX's latest filing, from $543.4 million in the prior quarter.
- Over five years, Current Assets peaked at $603.3 million in Q2 2025 and troughed at $253.3 million in Q2 2022.
- A 5-year average of $425.5 million and a median of $443.2 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets declined 19.51% in 2023, then soared 67.64% in 2024.
- Over 5 years, Current Assets stood at $357.0 million in 2022, then slipped by 8.4% to $327.0 million in 2023, then surged by 45.41% to $475.5 million in 2024, then rose by 14.28% to $543.4 million in 2025, then dropped by 6.18% to $509.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $509.8 million, $543.4 million, and $573.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 471.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 471.52 Mn |
| Mar 31, 2026 | 509.79 Mn |
| Dec 31, 2025 | 543.39 Mn |
| Sep 30, 2025 | 573.90 Mn |
| Jun 30, 2025 | 603.26 Mn |
| Mar 31, 2025 | 443.18 Mn |
| Dec 31, 2024 | 475.48 Mn |
| Sep 30, 2024 | 499.44 Mn |
| Jun 30, 2024 | 519.44 Mn |
| Mar 31, 2024 | 541.43 Mn |
| Dec 31, 2023 | 327.00 Mn |
| Sep 30, 2023 | 297.92 Mn |
| Jun 30, 2023 | 317.00 Mn |
| Mar 31, 2023 | 333.36 Mn |
| Dec 31, 2022 | 357.00 Mn |
| Sep 30, 2022 | 370.14 Mn |
| Jun 30, 2022 | 253.34 Mn |
| Mar 31, 2022 | 268.62 Mn |
| Dec 31, 2021 | 283.77 Mn |
| Sep 30, 2021 | 293.24 Mn |